A Case of Inflammatory Nonscarring Alopecia Associated With the Tyrosine Kinase Inhibitor Nilotinib

    March 2013 in “ JAMA Dermatology ”
    Timothy J. Hansen, Anthony J. Little, Jeffrey J. Miller, Michael D. Ioffreda
    Studysummary This case study describes a 33-year-old woman with chronic myelogenous leukemia who developed nonscarring alopecia after starting nilotinib therapy, linked to perifollicular inflammation.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jamanetwork.com →
    Discuss this study in the Community →

    Research cited in this study 4

    1. Scarring Alopecia Associated With the Epidermal Growth Factor Receptor Inhibitor Erlotinib Journal of the American Academy of Dermatology · 2011
    2. Nonscarring Inflammatory Alopecia Associated With the Epidermal Growth Factor Receptor Inhibitor Gefitinib Journal of the American Academy of Dermatology · 2006
    3. PDGF Isoforms Induce and Maintain Anagen Phase of Murine Hair Follicles Journal of Dermatological Science · 2006
    4. Genetically Null Mice Reveal a Central Role for Epidermal Growth Factor Receptor in the Differentiation of the Hair Follicle and Normal Hair Development PubMed · 1997

    Related research 1

    1. A Case of Inflammatory Nonscarring Alopecia Associated With the Tyrosine Kinase Inhibitor Nilotinib JAMA Dermatology · 2013